Acquisitions and olmesartan weakness to weigh on Daiichi Sankyo this year
This article was originally published in Scrip
Executive Summary
Daiichi Sankyo expects its sales to remain virtually static this fiscal year, held back by weakness for its top product olmesartan and the loss of exclusivity for levofloxacin in the US, along with a lower contribution from Indian unit Ranbaxy.